"People on a regimen containing efavirenz (Sustiva or Atripla) had a higher risk of having low vitamin D levels—which can lead to bone problems—than people on a protease inhibitor regimen. The study, which also found race and season of the year to play a role in vitamin D levels, was presented at the Fifth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town. ...
"Welz’s team found that low vitamin D levels were nearly universal in their cohort of patients, but that certain groups were much more likely to have very low levels. Those with very low vitamin D levels included black patients, patients whose levels were tested during the winter, and patients currently taking efavirenz."
Read more in POZ, July 23, 2009.
Note: The patients in this study were treated in London.
0 comments:
Post a Comment